Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. Pediatr Infect Dis J, 33(8), 865-71. presented at the 2014 Aug. doi:10.1097/INF.0000000000000329. (2014).
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA, 314(3), 237-46. presented at the 2015 Jul 21. doi:10.1001/jama.2015.7916. (2015).
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis, 197(5), 667-75. presented at the 2008 Mar 01. doi:10.1086/527489. (2008).
Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis, 197(4), 580-3. presented at the 2008 Feb 15. doi:10.1086/526537. (2008).
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis, 198(5), 635-41. presented at the 2008 Sep 01. doi:10.1086/590916. (2008).
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis, 206(6), 811-20. presented at the 2012 Sep 15. doi:10.1093/infdis/jis427. (2012).
Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis, 204(6), 854-63. presented at the 2011 Sep 15. doi:10.1093/infdis/jir440. (2011).
Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine, 30(28), 4240-8. presented at the 2012 Jun 13. doi:10.1016/j.vaccine.2012.04.044. (2012).
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine, 33(1), 163-73. presented at the 2015 Jan 01. doi:10.1016/j.vaccine.2014.10.083. (2015).
Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol, 16(4), 558-66. presented at the 2009 Apr. doi:10.1128/CVI.00368-08. (2009).
Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. J Infect Dis, 206(6), 828-37. presented at the 2012 Sep 15. doi:10.1093/infdis/jis445. (2012).
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis, 198(9), 1309-16. presented at the 2008 Nov 01. doi:10.1086/592172. (2008).
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA, 312(14), 1409-19. presented at the 2014 Oct 08. doi:10.1001/jama.2014.12854. (2014).